EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Current Pharmaceutical Strategies for the Long-Term Management of Addiction

Mohamed F. Zayed, Hussein M. Farag

Pharmaceuticals · 28.10.2026 · 19 (11) · 1699

DOI: 10.3390/ph19111699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 28.10.2026. Verfasst von Mohamed F. Zayed und 1 weiteren Autor:innen. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Substance use disorders (SUDs) are chronic, progressive brain diseases that result in continued liability to relapse, even after periods of abstinence.

Objectives

This review synthesizes current evidence for a paradigm shift in addiction medicine: from suppression of acute drug effects to repair of the neurobiological substrates underlying relapse vulnerability.

Method

We used medical databases to conduct an electronic search to identify the objectives. We reviewed in detail the existing pharmacotherapies for SUD, discussing their mechanisms of action, efficacy data, and limitations. We then reviewed novel drug classes that target resilience-promoting mechanisms to conclude a comprehensive roadmap for the management of addiction.

Result

Novel drug classes that target resilience-promoting mechanisms, including GLP-1 receptor agonists that modulate mesolimbic dopamine signaling, orexin receptor antagonists that target stress-induced craving, kappa-opioid receptor antagonists that counteract stress-induced dysphoria, and corticotropin-releasing factor (CRF) antagonists that normalize hypothalamic–pituitary–adrenal (HPA) axis dysfunction. Furthermore, agents that stimulate neuroplasticity (ibogaine, noribogaine, glutamate modulators) and agents that target neuroinflammation (endocannabinoid modulators, microglial inhibitors), and biological interventions, including immunopharmacotherapy and psychedelic-assisted therapies, are new strategies for long-term management of addiction.

Conclusions

Long-term management of addiction should provide a comprehensive roadmap to the development of next-generation addiction therapeutics that restore neural circuit function and promote long-lasting resilience to relapse for medicinal chemists and neuroscientists.

Zitieren

APA

Zayed, M. F., & Farag, H. M. (2026). Current Pharmaceutical Strategies for the Long-Term Management of Addiction. Pharmaceuticals, 19(11), 1699. https://doi.org/10.3390/ph19111699

Vancouver

Zayed MF, Farag HM. Current Pharmaceutical Strategies for the Long-Term Management of Addiction. Pharmaceuticals. 2026;19(11):1699. doi:10.3390/ph19111699

BibTeX
@article{Zayed2026,
  author = {Zayed, Mohamed F. and Farag, Hussein M.},
  title = {Current Pharmaceutical Strategies for the Long-Term Management of Addiction},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1699},
  doi = {10.3390/ph19111699}
}
Kostenlos starten →